This trial is testing the effects of two drugs, pembrolizumab and lenvatinib, on patients with high-grade serous ovarian cancer. The drugs work in different ways to attack the cancer cells, and it is hoped that they will be more effective together than either one alone.
2 Primary · 0 Secondary · Reporting Duration: through study completion, an average of 1 year
16 Total Participants · 2 Treatment Groups
Primary Treatment: Pembrolizumab · No Placebo Group · Phase 2
Age 18+ · Female Participants · 10 Total Inclusion CriteriaMark “Yes” if the following statements are true for you:
|18 - 65||100.0%|
|M D Anderson Cancer Center||100.0%|